Cardiome Oxyprim Phase IV Trial Design Will Be Part Of Chronic Gout Trial Design Cmte. Meeting
This article was originally published in The Pink Sheet Daily
The Phase IV proposal will act as a case study for FDA's Arthritis Advisory Committee's discussion June 2. The study will fulfill accelerated approval requirements for oxypurinol, which has a June 23 user fee date. The committee will also look at acute gout; Merck's Arcoxia will be discussed.
You may also be interested in...
Surrogate endpoint should seek a reduction in serum uric acid to a level of 6 mg/dL. Clinical outcome trials to confirm benefits of chronic gout products through reduction in gouty attacks should be carried out post-approval.
In Part 2 of Scrip’s roundtable, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors discuss how the pandemic brought in new investors and triggered strategic shifts for the biopharma industry.